{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:38:54Z","timestamp":1792215534231,"version":"4.4.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0611-3","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T08:02:44Z","timestamp":1562745764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5716-9665","authenticated-orcid":false,"given":"Paola","family":"Dama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"issue":"3","key":"611_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1389450116666150518095346","volume":"18","author":"Hanna Knaus","year":"2017","unstructured":"Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017). Immunomodulatory drugs: immune checkpoint agents in acute leukemia. Curr Drug Targets, 18(3), 315\u2013331. [PMCID: PMC4729661] [DOI: \n                    https:\/\/doi.org\/10.2174\/1389450116666150518095346\n                    \n                  ].","journal-title":"Current Drug Targets"},{"issue":"5","key":"611_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.21723","volume":"106","author":"Hagop Kantarjian","year":"2006","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090\u20131098. [PMID: 16435386] [DOI: \n                    https:\/\/doi.org\/10.1002\/cncr.21723\n                    \n                  ].","journal-title":"Cancer"},{"issue":"4","key":"611_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377. [PMID: 21172891. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.4310\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"22","key":"611_CR4","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/cncr.30203","volume":"122","author":"Tapan M. Kadia","year":"2016","unstructured":"Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy and outcomes. Cancer. 2016. [PMCID: PMC5269552] [DOI: \n                    https:\/\/doi.org\/10.1002\/cncr.30203\n                    \n                  ].","journal-title":"Cancer"},{"issue":"8","key":"611_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"L. Zhang","year":"2009","unstructured":"Zhang, L., Gajewski, T. F., & Kline, J. (2009). PD-1 \/ PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 114(8), 1545\u20131552. [PMCID: PMC2731636] [DOI: \n                    https:\/\/doi.org\/10.1182\/blood-2009-03-206672\n                    \n                  ].","journal-title":"Blood"},{"issue":"17","key":"611_CR6","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q. Zhou","year":"2011","unstructured":"Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., \u2026 Blazar, B. R. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117(17), 4501\u20134510. [PMCID: PMC3099570] [DOI: \n                    https:\/\/doi.org\/10.1182\/blood-2010-10-310425\n                    \n                  ].","journal-title":"Blood"},{"key":"611_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"611_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280\u20138 [PMCID: PMC4032802]. \n                    https:\/\/doi.org\/10.1038\/leu.2013.355\n                    \n                  .","journal-title":"Leukemia"},{"issue":"5","key":"611_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1586\/17474086.2016.1158096","volume":"9","author":"N Daver","year":"2016","unstructured":"Daver N, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol. 2016;9(5):433\u201345. \n                    https:\/\/doi.org\/10.1586\/17474086.2016.1158096\n                    \n                  .","journal-title":"Expert Rev Hematol"},{"key":"611_CR10","doi-asserted-by":"publisher","unstructured":"Shohei Koyama and others, \u2018Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated with Upregulation of Alternative Immune Checkpoints.\u2019, Nature Communications, 7 (2016), 10501 [PMCID: PMC4757784] [DOI: \n                    https:\/\/doi.org\/10.1038\/ncomms10501\n                    \n                  ].","DOI":"10.1038\/ncomms10501"},{"issue":"8","key":"611_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","volume":"32","author":"Kaori Sakuishi","year":"2011","unstructured":"Kaori Sakuishi and others, \u2018Emerging Tim-3 Functions in Antimicrobial and Tumor Immunity.\u2019, Trends in Immunology, 32.8 (2011), 345\u201349 [PMCID: PMC3164311][DOI: 10.1016\/j.it.2011.05.003].","journal-title":"Trends in Immunology"},{"key":"611_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al. Th1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u201341.","journal-title":"Nature"},{"issue":"12","key":"611_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"Chen Zhu","year":"2005","unstructured":"Zhu, C., et al., The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005. 6(12): p. 1245-1252. [PMID: 16286920] [DOI: \n                    https:\/\/doi.org\/10.1038\/ni1271\n                    \n                  ].","journal-title":"Nature Immunology"},{"key":"611_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A Sanchez-Fueyo","year":"2003","unstructured":"Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, et al. TIM-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093\u2013101.","journal-title":"Nat Immunol"},{"key":"611_CR15","doi-asserted-by":"publisher","unstructured":"Amy Y Wang and others, \u2018A Phase I Study of Selinexor in Combination with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients with Acute Myeloid Leukemia.\u2019, Journal of Hematology & Oncology, 11.1 (2018), 4 [PMCID: PMC5756334] [DOI: \n                    https:\/\/doi.org\/10.1186\/s13045-017-0550-8\n                    \n                  ].","DOI":"10.1186\/s13045-017-0550-8"},{"key":"611_CR16","doi-asserted-by":"publisher","unstructured":"Alexander TB, Lacayo NJ, Choi JK, Ribeiro RC, Pui CH, Rubnitz JE. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol 2016;34(34):4094\u20134101. \n                    https:\/\/doi.org\/10.1200\/JCO\n                    \n                  . 2016.67.5066.","DOI":"10.1200\/JCO"},{"issue":"20","key":"611_CR17","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","volume":"121","author":"K. Kojima","year":"2013","unstructured":"Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166\u20134174. https:\/\/doi. org\/10.1182\/blood-2012-08-447581","journal-title":"Blood"},{"key":"611_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/ijh-2018-0001","volume":"7","author":"C Talati","year":"2018","unstructured":"Talati C, Sweet KL. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. Int J Hematol Oncol. 2018;7:3.","journal-title":"Int J Hematol Oncol"},{"issue":"3","key":"611_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374. [PMID: 19880497. \n                    https:\/\/doi.org\/10.1182\/blood-2009-07-235358\n                    \n                  .","journal-title":"Blood."},{"issue":"24","key":"611_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139. [PMID: 14673054. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.04.036\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"611_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2012.12.012","volume":"152","author":"S Schwitalla","year":"2013","unstructured":"Schwitalla S, et al. Intestinal tumorigenesis initiated by dedifferentiation and Acquisition of Stem-Cell-like Properties. Cell. 2013;152(1\u20132):25\u201338. \n                    https:\/\/doi.org\/10.1016\/j.cell.2012.12.012\n                    \n                  .","journal-title":"Cell"},{"issue":"3","key":"611_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, et al. A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341\u201352. \n                    https:\/\/doi.org\/10.1016\/j.stem.2015.07.011\n                    \n                  .","journal-title":"Cell Stem Cell"},{"issue":"3","key":"611_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1535-7163.MCT-16-0496","volume":"16","author":"PM Tyler","year":"2017","unstructured":"Tyler PM, Servos MM, de Vries RC, et al. Clinical dosing regimen of Selinexor maintains Normal immune homeostasis and T-cell effector function in mice: implications for combination with immunotherapy. Mol Cancer Ther. 2017;16(3):428\u201339. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0496\n                    \n                  .","journal-title":"Mol Cancer Ther"},{"key":"611_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","volume":"8","author":"B Jia","year":"2018","unstructured":"Jia B, et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer Journal. 2018;8:34. \n                    https:\/\/doi.org\/10.1038\/s41408-018-0069-4\n                    \n                  .","journal-title":"Blood Cancer Journal"},{"issue":"5","key":"611_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","volume":"31","author":"Manar S Shafat","year":"2017","unstructured":"Shafat MS, Gnaneswaran Bruno, Bowles KM, Rushworth SA. The bone microenvironment-home of the leukemic blasts Blood Rev 2017;31(5):277\u2013286. doi: \n                    https:\/\/doi.org\/10.1016\/j.blre.2017.03.004\n                    \n                  . Epub 2017 Mar 12.","journal-title":"Blood Reviews"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0611-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:41Z","timestamp":1601041481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0611-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0611-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"175"}}